Incidence and Survival of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Cirrhosis Who Were Treated with and without Metformin
Thanida Tangjarusritaratorn,1 Watip Tangjittipokin,1,2 Tada Kunavisarut3 1Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 2Siriraj Center of Research Excellence in Diabetes and Obesity, Faculty of Medicine Siriraj Hospital, Mahidol University, B...
Enregistré dans:
Auteurs principaux: | Tangjarusritaratorn T, Tangjittipokin W, Kunavisarut T |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/787f455f97a7478ba6323a62a4c54adf |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma
par: Yelena Lapidot, et autres
Publié: (2020) -
Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application
par: Amir Mohamed Abdelhamid, et autres
Publié: (2022) -
Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
par: Magda Ibrahim, et autres
Publié: (2020) -
Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
par: Ng KJ, et autres
Publié: (2016) -
Undifferentiated shock in a cirrhotic patient: Ascites matters
par: Antigoni Xenou, et autres
Publié: (2021)